Study Published in Nature Shows F-Star's STING Agonist SB 11285 Enhances Preclinical Efficacy ...
Press release content from Globe Newswire. The AP news staff was not involved in its creation. Study Published in Nature Shows F-Star’s STING Agonist SB 11285 Enhances Preclinical Efficacy ... F-star Therapeutics, Inc.April 19, 2021 GMT SB 11285 in Combination with Radiation is More Effective than Either as Monotherapy in a Murine Tumor Model SB 11285 is a Second Generation STING Agonist Delivered Intravenously CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., April 19, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to...